MwanzoMYCOD • OTCMKTS
add
Mydecine Innovations Group Inc
Bei iliyotangulia
$Â 0.24
Bei za mwaka
$Â 0.0050 - $Â 0.48
Thamani ya kampuni katika soko
elfu 222.32 CAD
Wastani wa hisa zilizouzwa
564.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
CNSX
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (CAD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | elfu 243.28 | -89.22% |
Mapato halisi | elfu -12.95 | 99.51% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | — | — |
EBITDA | — | — |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (CAD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 234.00 | -98.28% |
Jumla ya mali | 234.00 | -99.85% |
Jumla ya dhima | 15.32M | -1.88% |
Jumla ya hisa | -15.32M | — |
hisa zilizosalia | 1.24M | — |
Uwiano wa bei na thamani | -0.02 | — |
Faida inayotokana na mali | -12,084.32% | — |
Faida inayotokana mtaji | 7.37% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (CAD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | elfu -12.95 | 99.51% |
Pesa kutokana na shughuli | elfu -9.60 | 1.52% |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | elfu -9.60 | 1.52% |
Mtiririko huru wa pesa | elfu -165.14 | -127.49% |
Kuhusu
Mydecine Innovations Group, or simply Mydecine, is an American and Canadian pharmaceutical company that is developing psychedelics and entactogens as medicines.
In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations. However, the company was able to obtain more funding and did not shutdown. Mydecine made the first legal import of magic mushrooms into Canada in 2021.
Mydecine's drug candidates include the psychedelics psilocybin, MYCO-004, and MYCO-005 and the novel MDMA-like entactogens MYCO-002, MYCO-006, and MYCO-007.
Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented 5-BZT-MDMA and 6-BZT-MDMA as short-acting MDMA analogues. Wikipedia
Ilianzishwa
2013
Makao Makuu
Tovuti
Wafanyakazi
3
